Cat. No.
MABL-3706
Application
inhibit, neutralize, therapeutic, WB, ELISA
Isotype
Engineer antibody
Species Reactivity
Human, Cynomolgus Monkey, Mouse
Clone No.
h15D2 (Fletikumab)
From
Recombinant Antibody
Specificity
This antibody binds a linear epitope comprising amino acids 'YQTPDHYTLRKISSLANSFLTIK' of the human Interleukin-20. It also cross reacts with mouse and cynomolgus monkey IL-20 . IL-20 is a pro- inflammatory and angiogenic cytokine mainly secreted by monocytes, granulocytes, dendritic cells and skin keratinocytes that plays crucial roles in immune responses, regulation of inflammatory responses, hemopoiesis, as well as epidermal cell and keratinocyte differentiation. IL-20 shows effects in several inflammatory diseases, such as rheumatoid arthritis, atherosclerosis, cancer, and liver fibrosis via regulating cytokines and chemokines. IL-20 acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1.
Alternative Names
IL20; Interleukin-20; ZCYTO10; Cytokine Zcyto10; NN-8226; NNC-0109- 0012
UniProt
Q9NYY1
Immunogen
The original antibody was generated by immunizing mice by injecting subcutaneously 20 μg of human IL-20 in FCA followed by two injections with 20 μg of hIL20 in FIA.
Application Notes
This antibody can bind recombinant human IL-20 in an ELISA. This antibody was capable or neutralizing human IL20, cynomolgus IL20 and mouse IL20 induced proliferation of BaF-3(hIL20R) cells. This antibody can detect both native and denatured form of human IL-20 in a western blot. The original IgG4 version of this antibody, expressed in HEK293 cells, reacts with recombinant human IL-20 with a binding affinity of Kd= 32 pM (US8287861). It shows a very high potency in blocking IL-20 mediated activity on IL-20RA/IL-20RB and IL-22RA1/IL20R2 expressing cells with an IC50 value of 0.27 nM. It has a serum half-life of ~3 weeks in RA (Rheumatoid Arthritis) patients. Under the dose range from 0.05 to 3.0 mg/kg, Fletikumab was tolerable and non-toxic in patients with psoriasis. However, the clinical study was terminated because no apparent efficacy was observed. In the phase 2a trial, Fletikumab significantly reduced tender joint counts and swollen joint counts in seropositive RA patients (PMID: 30319661).
Antibody First Published
Note on publication
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
